Clinical trial

StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis in Cancer Patients Receiving Elective Inguinal Radiation Therapy

Name

SPASX018

Description

The aim of this study is to assess the efficacy and safety of StrataXRT® in comparison to standard of care (defined using the Common Terminology Criteria for Adverse Events \[CTCAE\], version 5.0) by assessing the severity of inguinal RD in patients receiving elective radiation therapy +/- systemic therapy to the bilateral inguinal nodes.

Trial arms

Trial start

2022-11-01

Estimated PCD

2024-12-01

Trial end

2025-12-01

Status

Recruiting

Treatment

StrataXRT

StrataXRT is a full contact flexible wound dressing for the prevention and treatment of radiation dermatitis. StrataXRT is a semi-occlusive, self-drying and transparent gel. When used as directed StrataXRT dries to form a protective layer that is gas permeable and waterproof which hydrates and protects compromised skin areas and superficial wounds from chemical and microbial invasion. StrataXRT may be directly applied to radiation dermatitis, compromised skin surfaces, superficial wounds and first and second degree burns.

Arms:

StrataXRT

Aquaphor

Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc. Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or cracked skin and lips; helps protect from the drying effects of wind and cold weather.

Arms:

Aquaphor

Size

Primary endpoint

Incidence of acute >grade 2 radiation dermatitis

Until 8 weeks post radiation therapy; up to 4 months

Eligibility criteria

Inclusion Criteria: * At least 18 years of age or older * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Life expectancy of at least 6 months * Biopsy-confirmed malignancy without gross nodal involvement of the right or left inguinal regions * Patients will receive elective radiation therapy to bilateral inguinal nodal regions prescribed to 45-50 Gy in 1.8-2 Gy fractions using photon or proton therapy * No known allergy to studied products * Able to give written informed consent, or have written consent given on their behalf * Patients who are able and willing to attend the post-radiation weekly skin assessment appointments * Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Abstinence is acceptable if preferred by patient. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Exclusion Criteria: * Patients with gross cancer involvement of either or both inguinal regions. * Patients who have received prior pelvic and/or inguinal radiation therapy. * Patients who cannot apply the studied products to the inguinal region or have it administered to them as required by this study. * Patients with any medical condition such as active connective tissue disorder that predisposes them to an increased risk of potentially severe radiation dermatitis. * Patients with existing rashes or wounds in either inguinal region at baseline. * Planned inguinal dissection within 90 days after completion of radiation therapy on this study. * Female patients who are pregnant or breast feeding. * Patients who are unable to give written informed consent, or are unable to have written consent given on their behalf.

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}}

Updated at

2023-03-30

1 organization

1 product

1 indication

Organization

Stratpharma

Product

Aquaphor

Indication

Radiation Dermatitis